MedTrace Logo

Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)

NCT05524857 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2024-04-23

No results posted yet for this study

Summary

The purpose of this research is to study the safety and tolerability and to establish the maximum tolerated dose (MTD) of the combination of two drugs, fedratinib and decitabine, for the treatment of advanced-phase MPNs.

Conditions

  • Myeloproliferative Neoplasm

Interventions

DRUG

Fedratinib Oral Capsule 300 mg

300 mg by mouth, once daily

DRUG

Decitabine 20 mg/m2

20 mg/m2 for injection, for intravenous use

DRUG

Fedratinib Oral Capsule 400 mg

400 mg by mouth, once daily

Sponsors & Collaborators

Principal Investigators

  • Joseph Jurcic, MD · Columbia University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-28
Primary Completion
2024-04-09
Completion
2024-04-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05524857 on ClinicalTrials.gov